Inovio Biomedical to Present at International DNA Vaccine Conference

SAN DIEGO--(Business Wire)--
Inovio Biomedical Corporation (NYSE Amex:INO), a leader in DNA vaccine design,
development and delivery, announced today that it will make multiple
presentations at the Annual Conference of DNA Vaccines in Asia 2009 being hosted
by the International Society of DNA Vaccines July 9 - 10 at the Beijing
International Convention Center. The conference, with the theme, "Advancing DNA
Vaccine Technology," is co-chaired by David B. Weiner, Ph.D., professor of
pathology, University of Pennsylvania School of Medicine, and chairman of
Inovio`s scientific advisory board.

Inovio scientists and associates will be making the following presentations:

Engineering Highly Immune Potent DNA Vaccines by Engineering Molecular Biology, Immunology and Physical Delivery In Vivo
Presidential Address and Keynote Lecture
David B. Weiner, Ph.D.
Thursday July 9
08:30 - 09:05
Location: 305BC

Immune Therapy by Electroporation
Plenary Session 2
Iacob Mathiesen, Ph.D., Managing Director, Inovio AS
Thursday July 9
11:00 - 12:10
Location: 305BC

Pandemic and Seasonal Influenza DNA Vaccines Delivered via Electroporation
Plenary Session 3
Niranjan Y. Sardesai, Ph.D., Sr. VP, Research & Development, Inovio Biomedical
Thursday July 9
13:10 - 14:55
Location: 305BC

Special Considerations for Multi-Component DNA Vaccine Production
Plenary Session 7
Henry Hebel, Chief Operating Officer, VGXI Inc.
Friday July 10
11:00 - 12:10
Location: 305BC

About Inovio Biomedical Corporation

Inovio Biomedical is engaged in the design, development, and delivery of a new
generation of vaccines, called DNA vaccines, focused on cancers and infectious
diseases. The company`s SynCon technology enables the design of DNA-based
vaccines capable of providing cross-protection against evolving, unmatched
strains of pathogens such as influenza. Inovio`s proprietary
electroporation-based DNA vaccine delivery technology has been shown by initial
human data to safely and significantly increase gene expression and immune
responses. Inovio`s clinical programs include HPV/cervical cancer (therapeutic)
and HIV vaccines. An IND has been filed for an avian influenza vaccine. Partners
and collaborators include Merck, Tripep, University of Southampton, University
of Pennsylvania, and HIV Vaccines Trial Network. Inovio`s product candidates and
technologies are protected by an extensive global intellectual property
portfolio. More information is available at www.inovio.com.

This press release contains certain forward-looking statements relating to our
plans to develop electroporation-based drug and gene delivery technologies and
DNA vaccines. Actual events or results may differ from the expectations set
forth herein as a result of a number of factors, including uncertainties
inherent in clinical trials and product development programs (including, but not
limited to, the fact that pre-clinical and clinical results referenced in this
release may not be indicative of results achievable in other trials or for other
indications and that results from one study may not necessarily be reflected or
supported by the results of other similar studies), the availability of funding
to support continuing research and studies in an effort to prove safety and
efficacy of electroporation technology as a delivery mechanism or develop viable
DNA vaccines, the availability or potential availability of alternative
therapies or treatments for the conditions targeted by the parties or their
collaborators, including alternatives that may be more efficacious or
cost-effective than any therapy or treatment that the parties and their
collaborators hope to develop, evaluation of potential opportunities, issues
involving patents and whether they or licenses to them will provide the parties
with meaningful protection from others using the covered technologies, whether
such proprietary rights are enforceable or defensible or infringe or allegedly
infringe on rights of others or can withstand claims of invalidity and whether
the combined company can finance or devote other significant resources that may
be necessary to prosecute, protect or defend them, the level of corporate
expenditures, assessments of the companies` combined technology by potential
corporate or other partners or collaborators, capital market conditions, our
ability to successfully integrate Inovio and VGX Pharmaceuticals, the impact of
government healthcare proposals, our ability to maintain listing of our common
stock under the rules and regulations of the NYSE Amex and other factors set
forth in our Annual Report on Form 10-K for the year ended December 31, 2008,
our Form 10-Q for the three months ended March 31, 2009, and other regulatory
filings from time to time, including our current report on Form 8-K reporting
the closing of the merger transaction with VGX Pharmaceuticals, Inc. There can
be no assurance that any product in Inovio`s pipeline will be successfully
developed or manufactured, that final results of clinical studies will be
supportive of regulatory approvals required to market licensed products, or that
any of the forward-looking information provided herein will be proven accurate.

Inovio Biomedical
Bernie Hertel, 858-410-3101 (Investors)
or
Richardson & Associates
Jeff Richardson, 805-491-8313 (Media)

Copyright Business Wire 2009